Business

Notice of Interim Results & Investor Presentation

Notice of Interim Results & Investor Presentation.

articleRenalytix PlcMarch 12, 20255/company/renalytix-plc/news/notice-of-interim-results-and-investor-presentation-32
Notice of Interim Results & Investor Presentation

About this update from Renalytix Plc

[{"type":"text","content":"\n\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nNotice of Interim Results and Investor Presentation\n \nLONDON and NEW YORK, 12 March 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), which is commercialising kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment for chronic kidney disease, will announce its unaudited interim results for the six months ended 31 December 2024 on Tuesday 18 March 2025.\n \nInvestor Presentations\n \nOn-line investor presentation\nJulian Baines, Executive Chairman, will be hosting a live interactive presentation on the Engage Investor platform, at 2:00pm (GMT) on 18 March 2025.\n \nRenalytix welcomes all current shareholders and interested investors to join and encourages investors to pre-submit questions. Investors can also submit questions at any time during the live presentation.\n \nInvestors can sign up to Engage Investor at no cost and follow Renalytix plc from their personalised investor hub. Register interest in this event here: https://engageinvestor.news/RENX_IP25\n \nA recording of the event will be available on the Engage Investor platform afterwards.\n \nIn-person investor presentation\nJulian Baines will also provide an in-person presentation relating to the Company's interim results at 5.30pm GMT on Tuesday 25 March 2025, which is open to all existing and potential shareholders. The Company welcomes investors to 75 King William Street, London, EC4N 7BE from 5.15pm for a 5.30pm start and will be followed by refreshments.\n \nIf you would like to attend, please contact Walbrook PR on 020 7933 8780 or email [email protected].\n \n \nFor further information, please contact:\n \n\n\n\n\nRenalytix plc\n\n\nwww.renalytix.com\n\n\n\n\nJames McCullough, CEO\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n\n\n\n\n\nStifel (Nominated Adviser and Joint Broker)\n\n\nTel: 020 7710 7600\n\n\n\n\nNicholas Moore / Nick Harland / Brough Ransom / Ben Good\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOberon Capital (Joint Broker)\n\n\nTel: 020 3179 5300\n\n\n\n\nMike Seabrook / Nick Lovering\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\n\n\nTel: 020 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Alice Woodings\n\n\nMob: 07980 541 893 / 07407 804 654\n\n\n\n\n\n...

More updates from Renalytix Plc